Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy for the treatment of ALS. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

Alpha Cognition Inc.

Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing novel treatments for under-served neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS). ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer’s type, with minimal gastrointestinal side-effects and novel routes of administration. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein.  It is in preclinical development for the treatment of ALS.  ALPHA-0602 is patented and has received Orphan Drug Designation from the FDA.

	Jul '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover
cash per share	0.81 -	0.11 85.83%	0.21 85.38%	0.03 85.53%
company equity multiplier	1.05 -	527.00 49,936.68%	1.43 99.73%	-2.24 256.70%	-0.52 76.72%
days of inventory outstanding
days of payables outstanding
days of sales outstanding
dividend yield
ebit per revenue
ebt per ebit	0.92 -	1.02 10.93%	1.69 66.01%	0.90 46.75%
effective tax rate		-0.13 -	-0.03 79.71%	-0.01 47.19%
enterprise value multiple	0.47 -	-6.46 1,467.51%	-3.71 42.56%	-1.02 72.48%
fixed asset turnover
free cash flow per share	-0.04 -	-0.11 138.95%	-0.19 77.45%	-0.14 27.03%
gross profit margin
interest coverage		-7.38 -	-21.90 196.89%	-77.88 255.61%
inventory turnover
long term debt to capitalization		1.00 -
net income per ebt	1 -	1 0%	1 0%	1 0%
net profit margin
operating cash flow per share	-0.04 -	-0.10 138.55%	-0.19 76.61%	-0.14 26.60%
operating profit margin
payables turnover
pretax profit margin
price fair value	0.98 -	2.43K 248,722.89%	5.85 99.76%	-11.00 288.17%
receivables turnover
return on assets	-0.14 -	-0.69 403.89%	-1.52 121.31%	-4.11 170.55%
return on capital employed	-0.16 -	-1.17 648.85%	-1.04 10.72%	12.17 1,265.99%
return on equity	-0.14 -	-361.33 252,032.29%	-2.16 99.40%	9.18 523.95%
total debt to capitalization		1.00 -	0.11 89.30%	-11.14 10,567.41%	-0.35 96.86%

COM:ALPHACOGNITION

Alpha Cognition Inc.

Market Cap

85.20M

Beta: -

Volume Today

88.53K

Avg: -

Preview